Kelun Pharmaceutical's subsidiary's core product, Luconsa TMT( sac-TMT), latest research data will be announced at the 2026 European Lung Cancer Conference.

MaticHoleFiller · 2026-03-26T17:37:24+00:00

Sichuan Kelun Pharmaceutical's subsidiary developed the targeted TROP2 antibody-drug conjugate, Sac-TMT, which will announce key clinical research results at the European Lung Cancer Conference. The drug has shown excellent performance in treating EGFR-mutant non-small cell lung cancer and has been approved for market launch and included in medical insurance.

MaticHoleFiller

2026-03-26 17:37:24

Abstract generation in progress

China Visitor Network Data
Sichuan Kelun Pharmaceutical Co., Ltd. recently announced that the final overall survival (OS) analysis results of its core product—an antibody-drug conjugate (ADC) targeting TROP2, sacituzumab govitecan (sac-TMT, brand name: Jatai Lai®)—from the pivotal clinical study (OptiTROP-Lung03) will be presented as a breakthrough abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark, from March 25 to 28, 2026. The study involved patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) who had previously received EGFR-TKI and platinum-based chemotherapy.

Latest study data show that as of December 11, 2025, with a median follow-up of 23.8 months, after adjusting for crossover to sac-TMT in the control group, the median OS was 20.0 months for the sac-TMT group and 11.2 months for the docetaxel control group, with a hazard ratio (HR) of 0.45. The 18-month OS rates were 54.7% and 9.1%, respectively. Without adjustment, the median OS was 20.0 months for sac-TMT and 13.5 months for docetaxel (HR 0.63). Additionally, the median progression-free survival (PFS) was 7.9 months versus 2.8 months (HR 0.23). Based on these positive results, sac-TMT has been approved by China’s National Medical Products Administration (NMPA) for this indication and has been included in the national medical insurance catalog.

Sacituzumab govitecan (sac-TMT) is an independently developed TROP2 ADC by Kelun Botech. Currently, four indications have been approved in China, two of which are included in the medical insurance. It is also the world’s first TROP2 ADC approved for lung cancer. Kelun Botech has authorized Merck to develop and commercialize the product outside Greater China, and Merck is conducting multiple phase III clinical trials globally. The release of these long-term survival data further consolidates the product’s position in the treatment of EGFR-mutant NSCLC.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes